BACKGROUND
Although safe and effective human papillomavirus (HPV) vaccines have been available since 2006, national introduction in low- and middle-income countries (LMICs) has progressed slowly. HPV vaccine adoption may have been shaped by evolving World Health Organization (WHO) recommendations, funding policies of G...
Jiyeon Suh, M. Brisson, E. Burger et al.· Expert Review of Vaccines· 0 citations
HPV vaccination holds considerable promise in reducing the burden of non-cervical cancers among women in LMICs, especially in regions with high incidence and limited access to care.
A. Tuli, M. Jit, K. Abbas et al.· BMJ Global Health· 1 citation
An open-source, end-to-end pipeline is built to simulate LLM performance in a hypothetical scenario where they were available to inform COVID-19 models developed during the first four months of 2020, and shows that current models can extract transmission parameters from unstructured literature accurately enough to info...
X. Yang, C. Y. Lee, B. Quilty et al.· medRxiv· 0 citations
A two-stage hybrid model combining a dynamic HPV transmission model with a natural history model of HPV-related disease progression is developed to project the long-term health impact of therapeutic HPV vaccines in China from 2025 to 2125 and supports continued investment in therapeutic HPV vaccine development.
Cheng-Hao Pan, Shang-Ying Hu, Ting-Ting You et al.· BMC Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
